Vnitr Lek 2011, 57(10):799-802

Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates - single centre experience

D. Vondráková¹, F. Málek^1,*, J. Dvořák², L. Šedivá¹, J. Kupec¹, J. Petrů¹, M. Táborský¹, P. Neužil¹

¹ Department of Cardiology, Cardiovascular Centre, Na Homolce Hospital, Prague, Head Assoc. Prof. Petr Neužil, M.D., CSc., FESC

² Czech National Institute of Health, Prague, Head Jitka Sosnovcová, Ing.

The aim of the present study was to evaluate the optimal medical therapy in the chronic heart failure (CHF) patients referred from the comunity centres and the outpatients cardiology clinics for the cardiac resynchronization therapy with defibrilator (CRTD) to the Department of Cardiology, Na Homolce Hospital with the device implantation between 1st January 2008 and 30st September 2009.

Methods:
The optimal medical therapy was analysed retrospectively from the medical records of 179 consecutive CHF patients NYHA class III-IV. Beta-blockers (BB) were used only in 81% subjects referred for CRTD, ACE inhibitors (ACEI) were used only in 68% patients Angiotensin receptor blockers (ARB) were used in 18 % subjects. ACEI or ARB were used in 81%, spironolacton was use in 59%. Recommended target DD for BB (carvedilol 25 mg bid) was used only in 13% subjects, recommended target DD for ACEI (enalapril 10 mg bid) was used only in 9.4% patients.

Results:
In the Department of Cardiology, the optimal medical therapy was changed after CRTD, BB were used in 95% subjects at discharge (p < 0.01) and the number of patients reaching at least of 50% of recommended daily dose (DD) of BB increased (p < 0.05). ACEI were recommended after CRTD in 80% subjects after implantation (p < 0.05), the number of patients reaching at least of 50% of recommended DD for ACEIs increased too (p < 0.05). There was no significant difference in ARB use recomended in the hospital (19% after CRTD - NS). ACEI or ARB were used in 98% patients after the device implanted (p < 0.05) and spironolacton in 77% after CRTD (p < 0.05).

Conclusions:
Despite optimal composition of the optimal medical heart failure therapy only small number of CRTD candidates are reaching recommended drug dose. The optimization of the medical therapy in the specialized center lead to significantly higher proportion of CHF using the optimal therapy with the increased dose of BB and ACEI.

Keywords: chronic heart failure; cardiac resynchronization therapy; optimal medical therapy

Received: December 24, 2010; Accepted: March 10, 2011; Published: October 1, 2011  Show citation